Latest news about Dr. Lal Path Labs
Dr. Lal Path Labs
3,054.10
+58.90(+1.97%)
Company Performance:
View Company Insights1D+1.97%
1M-3.16%
6M+7.15%
1Y+2.80%
5Y+36.52%
More news about Dr. Lal Path Labs
31Oct 25
Dr. Lal PathLabs Announces Second Interim Dividend and 1:1 Bonus Share Issue
Dr. Lal PathLabs has declared a second interim dividend of INR 7.00 per share for FY 2025-26, with a record date of November 7, 2025. The company also announced a 1:1 bonus share issue, subject to approvals. To facilitate this, the authorized share capital will be increased from INR 1,07,96,00,000 to INR 2,00,00,00,000. The bonus shares will be issued from the Securities Premium Account and are expected to be credited by December 30, 2025. For Q2 2025, the company reported consolidated revenue of INR 7,548.00 million and profit after tax of INR 1,333.00 million.
31Oct 25
Dr. Lal PathLabs Reports Q2 Revenue Growth and Announces 1:1 Bonus Share Issue
Dr. Lal PathLabs reported robust Q2 financial results with revenue increasing to 7.30 billion rupees from 6.60 billion rupees year-over-year. The company's EBITDA rose to 2.24 billion rupees, maintaining a healthy margin of 30.7%. Consolidated net profit grew to 1.51 billion rupees. The Board approved a 1:1 bonus share issue, where shareholders will receive one new fully paid-up equity share for every existing share. Additionally, the company declared a second interim dividend of INR 7 per share, plans to increase its authorized share capital, and introduced an Employee Restricted Stock Unit Plan.
27Oct 25
Dr Lal Path Labs to Consider Bonus Share Issuance on October 31
Dr. Lal Path Labs' board of directors will meet on October 31 to consider issuing bonus shares to existing shareholders. Bonus shares are additional shares given to shareholders at no extra cost, proportional to their current holdings. This potential corporate action could increase the number of shares for existing shareholders without changing their proportional ownership. The final decision will be communicated after the board meeting.
24Oct 25
Dr Lal PathLabs Board to Consider Bonus Shares and Second Interim Dividend
Dr. Lal PathLabs' board will meet on October 31, 2025, to discuss potential bonus share issuance and a second interim dividend declaration. The meeting will also review Q2 and H1 FY2025-26 financial results. The company recently reported a 24% increase in net profit to ₹132 crore and 11.3% revenue growth to ₹670 crore. The trading window for company securities is closed until November 2, 2025.
24Sept 25
Dr. Lal PathLabs to Acquire ₹74.51 Crore Property in New Delhi's Shalimar Bagh
Dr. Lal PathLabs has announced plans to acquire immovable property in New Delhi for up to ₹74.51 crores, excluding additional costs. The property, located in Shalimar Bagh, includes four units across two floors, a ground floor shop, basement space, and parking area. The acquisition involves multiple parties and is subject to regulatory approvals. This move aligns with the company's strategy to strengthen its presence in key markets.
05Sept 25
Dr. Lal PathLabs Sees Rs. 81.60 Crore Block Trade on NSE
A significant block trade of Dr. Lal PathLabs shares occurred on the National Stock Exchange (NSE). The transaction involved 250,606 shares at Rs. 3,256.30 per share, totaling Rs. 81.60 crores. This large-scale trade highlights the liquidity of the company's stock and potential interest from institutional investors.
20Aug 25
Dr. Lal Path Labs Pioneers AI-Driven Cancer Diagnostics in India
Dr. Lal Path Labs, a leading Indian diagnostic chain, is integrating artificial intelligence (AI) technology into cancer diagnosis. This initiative aims to enhance diagnostic accuracy, enable earlier detection, and provide faster results in oncology. The company's adoption of AI for analyzing complex medical data, including pathology slides and imaging results, positions it at the forefront of technological advancement in India's medical diagnostics field. This move is expected to improve patient care and potentially increase accessibility to advanced diagnostic capabilities across India.
01Aug 25
Dr Lal PathLabs Reports 24% Profit Growth, Plans Southern India Expansion with ₹1,400 Crore Cash
Dr. Lal PathLabs reported robust Q1 FY24 results with a 24% YoY increase in net profit to ₹132.00 crore and 11.30% revenue growth to ₹670.00 crore. The company served 23.40 million patients, up from 21.10 million last year. CEO Shankha Banerjee announced plans to expand in southern India through acquisitions, with ₹1,400.00 crore available for this purpose. The company maintains its 11-12% revenue growth guidance and may revise EBITDA margin guidance upward from the initial 27% target.
31Jul 25
Dr. Lal PathLabs Announces ₹6 Per Share Interim Dividend
Dr. Lal PathLabs Limited has announced an interim dividend of ₹6 per equity share for the financial year 2025-26. The dividend, representing 60% of the face value of ₹10 per share, was approved in a board meeting on July 31, 2025. Shareholders on record as of August 06, 2025, will be eligible, with disbursement expected within 30 days of declaration. The board also reviewed Q1 financial results and amended the Code of Practices for Fair Disclosure of Unpublished Price Sensitive Information.
31Jul 25
Dr. Lal PathLabs Posts 18% Surge in Q1 Net Profit, Declares Interim Dividend
Dr. Lal PathLabs announced robust Q1 2025-26 financial results, with net profit increasing by 18% to ₹1.30 billion and revenue rising 11.70% to ₹6.70 billion. The company declared an interim dividend of ₹6 per equity share. Operational updates include the completion of voluntary liquidation of Suburban Diagnostics and dissolution of Dr. Lal PathLabs Kenya Private Limited.
24Jul 25
Dr. Lal PathLabs Gears Up for Q1 FY26 Earnings Call, Board to Consider Interim Dividend
Dr. Lal PathLabs Ltd., a leading Indian diagnostic services provider, will hold its Q1 FY26 earnings conference call on July 31, 2025, at 4:30 PM IST. The call will discuss financial and operating performance for the quarter ended June 30, 2025. Key leadership, including Executive Chairman Dr. Arvind Lal, CEO Shankha Banerjee, and Group CFO Ved Prakash Goel, will participate. The company operates 298 clinical labs, 6,607 Patient Service Centers, and 12,365 Pick-up Points as of March 31, 2025. In FY2025, it processed 86 million samples from 28.80 million patients. The board will consider a potential interim dividend during the meeting.
25Jun 25
Dr. Lal PathLabs Boosts Genomics Capabilities with Cutting-Edge Illumina Technology
Dr. Lal Path Labs has acquired Illumina's NovaSeq X Series technology to boost its genetic testing and analysis services. This advanced equipment is expected to improve turnaround times, increase testing capacity, enhance accuracy in detecting genetic variations, and expand the range of genomic services offered. The move aligns with the trend towards personalized medicine and strengthens the company's position in the diagnostics market.
29Apr 25
Dr Lal PathLabs Sets Ambitious Growth Targets, Plans Expansion Across India
Dr Lal PathLabs announces plans to achieve a 27% margin by FY26, with expansion plans including 15-20 new laboratories focusing on southern and western India. The company reported impressive Q4 results with revenue up 10.50%, EBITDA up 17%, and net profit surging 81.20% year-over-year. The board recommended a final dividend of Rs 6.00 per share for FY25.
25Apr 25
Dr. Lal PathLabs Q4 Profit Soars 83%, Surpasses Expectations
Dr. Lal PathLabs Limited posted strong Q4 FY25 results with net profit up 83% YoY to Rs 154.80 crore, outpacing revenue growth of 10.5% to Rs 602.60 crore. EBITDA grew 17% to Rs 169.00 crore with improved margin of 28%. For FY25, revenue increased 10.50% to Rs 24,614.00 crore, while net profit rose 35.90% to Rs 4,922.00 crore. The company announced a final dividend of Rs 6.00 per share, bringing the total FY25 dividend to Rs 24.00 per share.
15Apr 25
Dr. Lal PathLabs Pioneers Advanced Amyloidosis Test in South Asia
Dr. Lal PathLabs has become the first diagnostic chain in South Asia to launch an advanced test for amyloidosis, a group of rare diseases characterized by abnormal protein buildup in organs. This breakthrough enhances early detection and management capabilities for these complex disorders. The introduction of this test demonstrates Dr. Lal PathLabs' commitment to innovation and could strengthen its market position in the diagnostic industry.
07Apr 25
Dr. Lal Path Labs Witnesses Significant Block Trade on NSE
A significant block trade of 101,444 shares of Dr. Lal Path Labs Ltd. occurred on the National Stock Exchange. The shares were traded at Rs. 2,448.00 each, totaling Rs. 24.83 crore. While the identities of the buyer and seller remain undisclosed, such large transactions often indicate strategic moves by institutional investors or major shareholders.
02Apr 25
Dr. Lal PathLabs Witnesses Substantial Block Trade on NSE
A significant block trade of Dr. Lal PathLabs Ltd. shares occurred on the National Stock Exchange (NSE). The transaction involved 593,348 shares at ₹2,406.50 per share, totaling ₹142.79 crore. This large-scale trade could potentially impact the company's short-term trading patterns and may indicate shifts in ownership or strategy among major investors.
05Mar 25
Dr. Lal PathLabs Sees Major Block Trade Worth ₹54.54 Crore on NSE
A significant block trade of approximately 227,175 shares of Dr. Lal PathLabs Ltd. occurred on the National Stock Exchange. The shares were traded at ₹2,400.75 each, totaling a transaction value of ₹54.54 crore. This large-scale trade has drawn market attention, potentially signaling shifts in institutional or large investor holdings.
27Feb 25
Dr. Lal Path Labs Witnesses Significant Block Trade on NSE
A significant block trade of 116,643 shares of Dr. Lal Path Labs Ltd. occurred on the NSE, valued at Rs. 27.26 crores. The average price per share was Rs. 2,336.95. This large transaction could potentially impact the stock's trading pattern in the short term.
Industry Peers
Chandan Healthcare
Metropolis Healthcare
Suraksha Diagnostic
Thyrocare TechnologiesDr. Lal Path Labs
Nidan Labs & Healthcare
Krsnaa Diagnostics
Sastasundar Ventures
Vijaya Diagnostic Centre
Aspira Pathlab
321.10
(-0.51%)
1,931.10
(-0.75%)
280.20
(+0.14%)
428.20
(-1.21%)
3,054.10
(+1.97%)
20.05
(-8.86%)
755.90
(-1.39%)
314.30
(+0.87%)
1,080.00
(+7.80%)
68.99
(+0.20%)
Get More Market Insights with
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
